What is the difference between Amycretin and Cagrilintide?

Amycretin is classified as: Unimolecular GLP-1 and amylin receptor co-agonist. Cagrilintide is classified as: Long-acting amylin (and calcitonin) receptor agonist / amylin analogue. Amycretin is investigational and is not an approved medicine. Cagrilintide is investigational and is not an approved medicine.

Is Amycretin or Cagrilintide approved?

Amycretin is investigational and is not an approved medicine. Cagrilintide is investigational and is not an approved medicine. Regulatory status by region is set out in the table above.

How much clinical trial evidence is tracked for Amycretin and Cagrilintide?

Peptide Science Daily tracks 21 registered clinical trials for Amycretin (evidence grade C) and 42 for Cagrilintide (evidence grade B).

Compound comparison

Amycretin vs Cagrilintide

This page sets Amycretin and Cagrilintide side by side using the data recorded on Peptide Science Daily: drug class, mechanism of action, regulatory status by region, the evidence grade assigned here, and the number of clinical trials tracked. It is a neutral, factual comparison and does not rank either compound or recommend one over the other.

Side-by-side comparison

Class: Amycretin
Unimolecular GLP-1 and amylin receptor co-agonist
Cagrilintide
Long-acting amylin (and calcitonin) receptor agonist / amylin analogue
Mechanism: Amycretin
In plain terms, amycretin is one molecule that acts on two appetite-regulating targets at once: the GLP-1 receptor, the target of drugs such as semaglutide, and the amylin receptor.
Cagrilintide
In plain terms, cagrilintide mimics amylin, a hormone released with insulin that promotes fullness and slows digestion.
United States (FDA): Amycretin
Not approved. Investigational only; in early-to-mid phase clinical development for obesity and not authorized for any indication.
Cagrilintide
Investigational; not approved as a standalone product. As part of the CagriSema combination (with semaglutide), a new drug application has been filed and an FDA decision is expected later in 2026.
European Union (EMA): Amycretin
Not authorized. Investigational; no EU marketing authorisation.
Cagrilintide
Not authorized; investigational, no marketing authorization.
Australia (TGA): Amycretin
Not registered on the Australian Register of Therapeutic Goods (ARTG). Investigational; not approved in Australia.
Cagrilintide
Not entered on the ARTG; investigational only and not approved for supply.
WADA: Amycretin
Not listed on the WADA Prohibited List and not in the 2026 Monitoring Program (which names only markers of semaglutide and tirzepatide).
Cagrilintide
Not listed on the WADA Prohibited List. Amylin analogues are not banned substances; as an investigational agent it falls outside approved therapeutic use.
Evidence grade: Amycretin
C
Cagrilintide
B
Tracked clinical trials: Amycretin
21
Cagrilintide
42
Full profile: Amycretin
Amycretin profile
Cagrilintide
Cagrilintide profile

Comparison of Amycretin and Cagrilintide by class, mechanism, regulatory status by region, evidence grade, and number of tracked clinical trials.
Attribute	Amycretin	Cagrilintide
Class	Unimolecular GLP-1 and amylin receptor co-agonist	Long-acting amylin (and calcitonin) receptor agonist / amylin analogue
Mechanism	In plain terms, amycretin is one molecule that acts on two appetite-regulating targets at once: the GLP-1 receptor, the target of drugs such as semaglutide, and the amylin receptor.	In plain terms, cagrilintide mimics amylin, a hormone released with insulin that promotes fullness and slows digestion.
United States (FDA)	Not approved. Investigational only; in early-to-mid phase clinical development for obesity and not authorized for any indication.	Investigational; not approved as a standalone product. As part of the CagriSema combination (with semaglutide), a new drug application has been filed and an FDA decision is expected later in 2026.
European Union (EMA)	Not authorized. Investigational; no EU marketing authorisation.	Not authorized; investigational, no marketing authorization.
Australia (TGA)	Not registered on the Australian Register of Therapeutic Goods (ARTG). Investigational; not approved in Australia.	Not entered on the ARTG; investigational only and not approved for supply.
WADA	Not listed on the WADA Prohibited List and not in the 2026 Monitoring Program (which names only markers of semaglutide and tirzepatide).	Not listed on the WADA Prohibited List. Amylin analogues are not banned substances; as an investigational agent it falls outside approved therapeutic use.
Evidence grade	C	B
Tracked clinical trials	21	42
Full profile	Amycretin profile	Cagrilintide profile

Common questions

What is the difference between Amycretin and Cagrilintide?: Amycretin is classified as: Unimolecular GLP-1 and amylin receptor co-agonist. Cagrilintide is classified as: Long-acting amylin (and calcitonin) receptor agonist / amylin analogue. Amycretin is investigational and is not an approved medicine. Cagrilintide is investigational and is not an approved medicine.
Is Amycretin or Cagrilintide approved?: Amycretin is investigational and is not an approved medicine. Cagrilintide is investigational and is not an approved medicine. Regulatory status by region is set out in the table above.
How much clinical trial evidence is tracked for Amycretin and Cagrilintide?: Peptide Science Daily tracks 21 registered clinical trials for Amycretin (evidence grade C) and 42 for Cagrilintide (evidence grade B).